#United States #Minnesota #Medical Device #Laplace Interventional #Tricuspid Valve

Laplace Interventional Inc. Raises $22M in Series C Funding to Propel Heart Valve Innovation

Recently, Laplace Interventional Inc., a Minnesota-based medical technology company, announced successful completion of its Series C financing round, securing a hefty $22 million. This funding was spearheaded by a prominent global strategic investor and included participation from several new and existing investors such as Aphelion Cardeation, Unorthodox Ventures, and Engage Venture Partners. The funds are intended to facilitate crucial steps in developing Laplace's groundbreaking transcatheter tricuspid valve technology.

This innovative device is designed to enhance the quality of life for patients suffering from Tricuspid Regurgitation (TR), a condition that affects blood circulation in the heart. The technology promises a revolutionary approach by delivering prosthetic valves through minimally invasive procedures, eliminating the need for open-heart surgery that often entails higher risk and extended recovery times.

"This rounds off our initial efforts to treat patients with TR using a specialty transcatheter heart valve replacement platform," noted Dr. Brandon Jones, Interventional Cardiologist and Medical Director of Structural Heart at Providence St. Vincent Medical Center in Portland, Oregon. During preliminary evaluations, three patients were treated in the Early Feasibility Study (EFS) with all of them being discharged in just 1-2 days post-procedure. Dr. Jones praised the efficiency and intuitive design of the Laplace system, which has shown outstanding performance in various challenging anatomical conditions.

Laplace has already enrolled 22 patients across the United States and 25 globally as part of their EFS study, yielding promising outcomes that further reinforce the technology's potential.

The company’s CEO, Ramji Iyer, PhD, expressed gratitude toward both their new and continued investors, emphasizing that this funding marks a pivotal milestone for Laplace Interventional. It is indicative of the progress they have made in recent years and sets a clear path toward launching a pivotal trial.

“Aphelion Cardeation, a venture fund committed to backing innovative healthcare solutions that align with the mission of the American Heart Association, is thrilled to be part of this financing round,” commented Ned Scheetz, Managing Partner at Aphelion Capital. He further highlighted the transformational potential of Laplace’s solution for treating TR, which can positively impact millions suffering from this heart disease globally.

Although Laplace Interventional is advancing their device through significant funding and promising early results, it’s important to note that their technology is still in the developmental phase and has yet to receive any form of regulatory approval, including from the FDA.

In summary, Laplace Interventional appears positioned for rapid advancements in the heart valve space, and with the support of its investors and medical professionals, they are paving the way to potentially revolutionize treatment options for patients with tricuspid valve issues. More information can be found on the company’s official website.